文献速递临床微生物质量管理与危急值

舒巴坦-度洛巴坦药敏试验方法开发及MIC与纸片扩散法质控范围

Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
PubMed 文献 · J Clin Microbiol · 2023-12-14

本研究针对舒巴坦-度洛巴坦(用于治疗ABC复合群所致HABP/VABP的β-内酰胺/β-内酰胺酶抑制剂组合)开发了肉汤微量稀释MIC法和纸片扩散法药敏试验,并建立了质控范围。采用固定4 µg/mL度洛巴坦的舒巴坦倍比稀释MIC法及10/10 µg纸片法均能最佳区分预测敏感与耐药菌株,选择A. baumannii NCTC 13304进行多实验室质控研究,按CLSI M23 Tier 2标准确定MIC质控范围0.5/4-2/4 µg/mL及抑菌圈直径24-30 mm,已获CLSI批准。

要点

  • 舒巴坦-度洛巴坦MIC法采用固定4 µg/mL度洛巴坦的舒巴坦倍比稀释,区分敏感与耐药株最佳。
  • 纸片扩散法选用10/10 µg舒巴坦/度洛巴坦纸片,与MIC法相关性好且区分力最佳。
  • A. baumannii NCTC 13304的CLSI批准质控范围:MIC 0.5/4-2/4 µg/mL,抑菌圈24-30 mm。

核心结论

  • 舒巴坦-度洛巴坦的肉汤微量稀释MIC法和纸片扩散法及相应质控范围已建立并获CLSI批准,可供临床实验室准确可重复地进行药敏试验。

研究设计与样本

  • 采用基因特征明确的鲍曼不动杆菌分离株面板,基于度洛巴坦对β-内酰胺酶抑制谱预测敏感或耐药,评估舒巴坦与度洛巴坦不同组合的MIC法。
  • 按CLSI M23 Tier 2标准进行多实验室质控研究,选择A. baumannii NCTC 13304作为质控菌株。

主要发现

  • 固定4 µg/mL度洛巴坦的舒巴坦倍比稀释MIC法对预测敏感与耐药菌株的区分力最大。
  • 舒巴坦/度洛巴坦10/10 µg纸片浓度区分力最佳且与MIC法相关性好。
  • A. baumannii NCTC 13304可同时评估舒巴坦和度洛巴坦活性且终点清晰。

关键数值与推荐

  • 舒巴坦-度洛巴坦肉汤微量稀释MIC质控范围:0.5/4-2/4 µg/mL(A. baumannii NCTC 13304)。
  • 舒巴坦-度洛巴坦纸片扩散法抑菌圈直径质控范围:24-30 mm(A. baumannii NCTC 13304)。
  • 上述质控范围已获CLSI批准。

临床怎么用

  • 临床实验室可采用固定4 µg/mL度洛巴坦的舒巴坦倍比稀释MIC法或10/10 µg纸片扩散法对ABC复合群进行舒巴坦-度洛巴坦药敏试验。
  • 使用A. baumannii NCTC 13304按CLSI批准的质控范围(MIC 0.5/4-2/4 µg/mL,抑菌圈24-30 mm)进行日常质控。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination developed to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Durlobactam is a diazabicyclooctane β-lactamase inhibitor with potent activity against Ambler classes A, C, and D serine β-lactamases and restores sulbactam activity against multidrug-resistant ABC. Studies were conducted to establish sulbactam-durlobactam antimicrobial susceptibility testing methods for both broth microdilution minimal inhibitory concentration (MIC) and disk diffusion tests as well as quality control (QC) ranges. To establish the MIC test method, combinations of sulbactam and durlobactam were evaluated using a panel of genetically characterized A. baumannii isolates which were categorized as predicted to be susceptible or resistant based on the spectrum of β-lactamase inhibition by durlobactam. MIC testing with doubling dilutions of sulbactam with a fixed concentration of 4 µg/mL of durlobactam resulted in the greatest discrimination of the pre-defined susceptible and resistant strains. Similarly, the sulbactam/durlobactam 10/10 µg disk concentration showed the best discrimination as well as correlation with the MIC test. A. baumannii NCTC 13304 was selected for QC purposes because it assesses the activity of both sulbactam and durlobactam with clear endpoints. Multi-laboratory QC studies were conducted according to CLSI M23 Tier 2 criteria. A sulbactam-durlobactam broth MIC QC range of 0.5/4-2/4 µg/mL and a zone diameter QC range of 24-30 mm were determined for A. baumannii NCTC 13304 and have been approved by CLSI. These studies will enable clinical laboratories to perform susceptibility tests with accurate and reproducible methods.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. McLeod SM, Carter NM, Huband MD, et al. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. J Clin Microbiol. 2023. PMID: 38095417. doi:10.1128/jcm.01228-23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。